Valeant Pharmaceuticals International (VRX) PT Set at $18.00 by Deutsche Bank

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) has been given a $18.00 price target by research analysts at Deutsche Bank in a research report issued to clients and investors on Thursday, November 16th. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Deutsche Bank’s target price indicates a potential upside of 1.41% from the company’s current price.

Several other analysts have also recently weighed in on VRX. HC Wainwright set a $17.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “sell” rating in a research note on Wednesday, August 9th. Canaccord Genuity set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Thursday, August 10th. Wells Fargo & Company reissued an “underperform” rating and issued a $8.00 price target on shares of Valeant Pharmaceuticals International in a research note on Saturday, September 30th. Finally, Jefferies Group restated a “buy” rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average price target of $17.46.

Valeant Pharmaceuticals International (VRX) traded up $0.26 during trading on Thursday, hitting $17.75. 13,494,267 shares of the stock traded hands, compared to its average volume of 17,770,209. Valeant Pharmaceuticals International has a twelve month low of $8.31 and a twelve month high of $18.25. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $6,150.00, a PE ratio of 2.80, a price-to-earnings-growth ratio of 0.47 and a beta of -0.22.

In other Valeant Pharmaceuticals International news, Director John Paulson bought 344,216 shares of Valeant Pharmaceuticals International stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, for a total transaction of $4,956,710.40. Following the acquisition, the director now directly owns 94,559 shares in the company, valued at $1,361,649.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.87% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in VRX. Dimensional Fund Advisors LP lifted its holdings in Valeant Pharmaceuticals International by 327.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after buying an additional 3,426,410 shares in the last quarter. Paulson & CO. Inc. lifted its holdings in Valeant Pharmaceuticals International by 12.5% during the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock worth $377,372,000 after buying an additional 2,428,900 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Valeant Pharmaceuticals International during the 2nd quarter worth approximately $41,574,000. Canada Pension Plan Investment Board lifted its holdings in Valeant Pharmaceuticals International by 24,953.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock worth $36,525,000 after buying an additional 2,096,100 shares in the last quarter. Finally, Cannell Peter B & Co. Inc. acquired a new stake in Valeant Pharmaceuticals International during the 2nd quarter worth approximately $20,981,000. Institutional investors own 49.49% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International (VRX) PT Set at $18.00 by Deutsche Bank” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/deutsche-bank-ag-analysts-give-valeant-pharmaceuticals-international-inc-vrx-a-18-00-price-target.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply